Legence (LGN) stock drops nearly 9% today as contractors slide ahead of U.S. payrolls

Legence (LGN) stock drops nearly 9% today as contractors slide ahead of U.S. payrolls

New York, Jan 8, 2026, 14:38 EST — Regular session

  • Legence shares slid about 9% in afternoon trading, reversing an early move higher
  • Contractor peers also fell, while Wall Street traded mixed ahead of key U.S. jobs data
  • Traders are watching Friday’s payrolls report and any further deal-related filings from Legence

Legence Corp (LGN.O) shares fell about 9% to $43.99 on Thursday, after earlier touching $48.79. The stock closed at $48.32 on Wednesday.

The pullback lands on a newly public name that has moved fast since its September debut. Blackstone-backed Legence raised $728 million in an IPO priced at $28 a share and sells engineering and maintenance work for building systems, including heating and air conditioning.

Broader markets offered little shelter. Wall Street was mixed on Thursday and traders focused on Friday’s nonfarm payrolls report for December, with technology shares weighing on the Nasdaq.

Other construction and engineering stocks were also lower: Comfort Systems USA was down about 7%, EMCOR about 5% and Quanta Services about 6%. Legence traded as low as $43.67 and volume topped 600,000 shares.

The company’s last major update came on Jan. 2, when it said it completed its acquisition of The Bowers Group, paying $325 million in cash and issuing about 2.55 million shares. Chief Executive Jeff Sprau called it “an important milestone in our growth strategy.” Legence

A regulatory filing showed Legence funded the cash portion with a mix that included a $200 million incremental term loan facility that it drew in full at closing. A term loan is long-term borrowing; the company said the incremental loans carry terms identical to its existing term debt and it expects to file deal financials and pro forma information within 71 days.

At its last quarterly report in November, Legence forecast 2026 revenue of $2.65 billion to $2.85 billion and adjusted EBITDA of $295 million to $315 million. Adjusted EBITDA is a non-GAAP profit gauge that backs out items like interest, taxes and depreciation to give a cleaner view of operating performance.

Thursday’s slide also took the shares back below $45, the price used in an upsized secondary offering by selling stockholders in December. The prospectus said Legence did not sell any shares in that deal and would not receive proceeds, and it warned that future stock sales could pressure the share price.

But big swings cut both ways for a fresh IPO with an acquisition and new borrowing in the mix. A hotter-than-expected jobs report could keep rate worries alive, and any stumble in integrating recent deals could hit margins.

Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Constellation Energy

NASDAQ: CEG 94 / 100
#3 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 92 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

AIG

NYSE: AIG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens
Previous Story

Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

MYR Group stock sinks nearly 8% as infrastructure contractors slide ahead of U.S. jobs data
Next Story

MYR Group stock sinks nearly 8% as infrastructure contractors slide ahead of U.S. jobs data